Rutazyme Lemon Fermented Product Capsules for Metabolic Function in Adults With Obesity

Recruiting now · Not applicable · Has a placebo group

Conditions studied: Obesity, Metabolic Syndrome

In brief

This study evaluates whether a fruit- and vegetable-based fermented product (Rutazyme® lemon fermented product) taken as a capsule can improve metabolic health in adults with obesity. Forty adults aged 18-65 years with obesity (BMI ≥ 27 kg/m² and waist circumference \> 90 cm for men or \> 80 cm for women) will be randomly assigned to receive either a Rutazyme® lemon fermented product capsule (500 mg) or a placebo capsule once daily at bedtime for 12 weeks. Before supplementation, participants will complete a 2-week stabilization period during which they maintain their usual diet and physical activity. Body composition and waist/hip measurements will be assessed during the study, and blood pressure will be monitored. Blood samples will be collected to evaluate metabolic and safety laboratory measures (e.g., lipids, glucose, insulin, inflammation markers, liver and kidney function), and stool samples will be collected to assess gut microbiota. Gut-brain axis biomarkers (GLP-1 and PYY) will be measured at multiple time points after capsule intake at baseline and at Week 12. The results will help determine the metabolic effects and safety of Rutazyme® lemon fermented product supplementation in adults with obesity.

Key facts

Study ID

NCT07540949

Run by

National Taiwan Sport University

People needed

40

Starts

2026-03-16

Expected to finish

2026-08-31

Last updated by the study team

2026-04-21

Who can join

Age: 18 and older, up to 65. Sex: any. Healthy volunteers: not accepted.

You may qualify if…

• Age 18 to 65 years.
• Body mass index (BMI) ≥ 27 kg/m².
• Waist circumference > 90 cm for men or > 80 cm for women.
• Able and willing to provide written informed consent and comply with study procedures.

You may not qualify if…

• Pregnant, breastfeeding, or menopausal or postmenopausal.
• Use of enzyme supplements or fiber supplements within the past month.
• Current treatment with antihypertensive medications.
• Gastrointestinal disorders, including inflammatory bowel disease (e.g., ulcerative colitis or Crohn's disease).
• Major cardiovascular, metabolic, or renal disease.
• Unable to provide informed consent or insufficient decision-making capacity.
• Investigator determines the participant is not suitable for the study.

Where it is running

• National Taiwan Sport University — Taoyuan, Taiwan (enrolling)

Full record on ClinicalTrials.gov

Trial information comes from ClinicalTrials.gov and is refreshed daily. TrialsForMe does not provide medical care and does not run the studies it lists.